Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MederaMDER Equity-to-Asset is -1.97 as of Jun. 2024.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Medera's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $-6.09 Mil. Medera's Total Assets for the quarter that ended in Jun. 2024 was $3.09 Mil.
Therefore, Medera's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was -1.97.
The historical rank and industry rank for Medera's Equity-to-Asset or its related term are showing as below:
MDER's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.69 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Medera Equity-to-Asset Related Terms
Medera Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Medera's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medera Equity-to-Asset Chart
Medera Annual Data
Trend
Dec22
Dec23
Equity-to-Asset
-8.27
-5.92
Medera Semi-Annual Data
Dec22
Jun23
Dec23
Jun24
Equity-to-Asset
-8.27
0.00
-5.92
-1.97
MDER vs : Equity-to-Asset Comparison
For the Biotechnology subindustry, Medera's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medera Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medera's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Medera's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Medera's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medera (MDER) has a Equity-to-Asset of -1.97 as of Jun. 2024. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medera and its competitors.
Is Medera's Equity-to-Asset too high?
Medera's current Equity-to-Asset is -1.97.
How does Medera's Equity-to-Asset compare to ?
Medera's Equity-to-Asset of -1.97 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medera and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medera's current Equity-to-Asset is -1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medera stock overvalued right now?
Medera (MDER) has a current Equity-to-Asset of -1.97. The current Equity-to-Asset is -1.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Medera (MDER), the current Equity-to-Asset is -1.97 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medera Inc is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates through two arms, namely: (1) pre-clinical disease modeling and drug discovery under Medera's Novoheart brand, which includes its bioengineered human mini-heart technology platform and related state-of-the-art technologies for preclinical screening; and (2) clinical development of novel therapies under Medera's Sardocor brand, which aspires to create the shortest regulatory path to clinic for advancing next-generation gene therapies (by leveraging the above Novoheart platform), in particular, for cardiovascular diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDER has been successfully added to your 
